Autogene cevumeran
- Generic Name
- Autogene cevumeran
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2365453-34-3
- Unique Ingredient Identifier
- L8HDH9IB06
- Background
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
- Associated Conditions
- -
- Associated Therapies
- -
Investigational mRNA Vaccine Induced Persistent Immune Response Against Pancreatic Cancer
The mRNA-based cancer vaccine autogene cevumeran shows promise in stimulating a durable immune response against pancreatic cancer, with T cells persisting up to three years post-treatment. A phase 1 trial revealed vaccine-induced T cells correlated with reduced cancer recurrence. A phase 2 trial is underway to further evaluate its efficacy and safety.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath